The DOI matches its Crossref record; 182 of the 182 references it cites were found in a registry or an index.
Neuroblastoma: developmental biology, cancer genomics and immunotherapy
Open accessAbstract
Neuroblastoma is a solid tumour that arises from the developing sympathetic nervous system. Over the past decade, our understanding of this disease has advanced tremendously. The future challenge is to apply the knowledge gained to developing risk-based therapies and, ultimately, improving outcome. In this Review we discuss the key discoveries in the developmental biology, molecular genetics and immunology of neuroblastoma, as well as new translational tools for bringing these promising scientific advances into the clinic.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Cancer immunotherapy comes of age
Mellman, I., Coukos, G., & Dranoff, G. (2011) · Nature · doi:10.1038/nature10673 · Cited by 3,893
Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm
Biswas, S. K., & Mantovani, A. (2010) · Nature Immunology · doi:10.1038/ni.1937 · Cited by 3,840
Le Douarin, N., & Kalcheim, C. (1999) · Cambridge University Press eBooks · doi:10.1017/cbo9780511897948 · Cited by 3,014
Massive genomic rearrangement acquired in a single catastrophic event during cancer development
Stephens, P. J., Greenman, C. D., Fu, B., Yang, F., Bignell, G. R., Mudie, L. J., Pleasance, E. D., Lau, K. W., Beare, D., Stebbings, L. A., et al. (2011) · Cell · doi:10.1016/j.cell.2010.11.055 · Cited by 2,414
Brodeur, G. M., Pritchard, J., Berthold, F., Carlsen, N. L., Castel, V, Castelberry, R. P., De Bernardi, B., Evans, A. E., Favrot, M., & Hedborg, F. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.8.1466 · Cited by 2,294
Amplification of N- myc in Untreated Human Neuroblastomas Correlates with Advanced Disease Stage
Brodeur, G. M., Seeger, R. C., Schwab, M., Varmus, H. E., & Bishop, J. M. (1984) · Science · doi:10.1126/science.6719137 · Cited by 2,262
Scott, A. M., Wolchok, J. D., & Old, L. J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3236 · Cited by 2,160
Neuroblastoma: biological insights into a clinical enigma
Brodeur, G. M. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1014 · Cited by 2,160
Intra-tumour heterogeneity: a looking glass for cancer?
Marusyk, A., Almendro, V., & Polyak, K. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3261 · Cited by 2,000
Recent Advances in Neuroblastoma
Maris, J. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0804577 · Cited by 1,983
The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force Report
Cohn, S. L., Pearson, A. D. J., London, W. B., Monclair, T., Ambros, P. F., Brodeur, G. M., Faldum, A., Hero, B., Iehara, T., Machin, D., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.6785 · Cited by 1,910
Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma
Yu, A. L., Gilman, A. L., Ozkaynak, M. F., London, W. B., Kreissman, S. G., Chen, H. X., Smith, M., Anderson, B., Villablanca, J. G., Matthay, K. K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0911123 · Cited by 1,835
Identification of ALK as a major familial neuroblastoma predisposition gene
Mossé, Y. P., Laudenslager, M., Longo, L., Cole, K. A., Wood, A., Attiyeh, E. F., Laquaglia, M. J., Sennett, R., Lynch, J. E., Perri, P., et al. (2008) · Nature · doi:10.1038/nature07261 · Cited by 1,407
Cheever, M. A., Allison, J. P., Ferris, A. S., Finn, O. J., Hastings, B. M., Hecht, T. T., Mellman, I., Prindiville, S. A., Viner, J. L., Weiner, L. M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0737 · Cited by 1,388
Humanized mice in translational biomedical research
Shultz, L. D., Ishikawa, F., & Greiner, D. L. (2007) · Nature Reviews Immunology · doi:10.1038/nri2017 · Cited by 1,279
Pule, M. A., Savoldo, B., Myers, G. D., Rossig, C., Russell, H. V., Dotti, G., Huls, M. H., Liu, E., Gee, A. P., Mei, Z., et al. (2008) · Nature Medicine · doi:10.1038/nm.1882 · Cited by 1,195
The genetic landscape of high-risk neuroblastoma
Pugh, T. J., Morozova, O., Attiyeh, E. F., Asgharzadeh, S., Wei, J. S., Auclair, D., Carter, S. L., Cibulskis, K., Hanna, M., Kiezun, A., et al. (2013) · Nature Genetics · doi:10.1038/ng.2529 · Cited by 1,186
Catecholamine Metabolism: A Contemporary View with Implications for Physiology and Medicine
Eisenhofer, G., Kopin, I. J., & Goldstein, D. S. (2004) · Pharmacological Reviews · doi:10.1124/pr.56.3.1 · Cited by 1,072
The International Neuroblastoma Pathology Classification (the Shimada system)
Shimada, H., Ambros, I. M., Dehner, L. P., Hata, J.-I., Joshi, V. V., Roald, B., Stram, D. O., Gerbing, R. B., Lukens, J. N., Matthay, K. K., et al. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19990715)86:2<364::aid-cncr21>3.0.co;2-7 · Cited by 1,067
Humanized mice in translational biomedical research
Shultz, L. (2007) · The Mouseion at the JAXlibrary (Jackson Laboratory) · Cited by 1,036
Oncogenic mutations of ALK kinase in neuroblastoma
Chen, Y., Takita, J., Choi, Y. L., Kato, M., Ohira, M., Sanada, M., Wang, L., Soda, M., Kikuchi, A., Igarashi, T., et al. (2008) · Nature · doi:10.1038/nature07399 · Cited by 916
Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma
Janoueix-Lerosey, I., Lequin, D., Brugières, L., Ribeiro, A., de Pontual, L., Combaret, V., Raynal, V., Puisieux, A., Schleiermacher, G., Pierron, G., et al. (2008) · Nature · doi:10.1038/nature07398 · Cited by 894
Activating mutations in ALK provide a therapeutic target in neuroblastoma
George, R. E., Sanda, T., Hanna, M., Fröhling, S., II, W. L., Zhang, J., Ahn, Y., Zhou, W., London, W. B., McGrady, P., et al. (2008) · Nature · doi:10.1038/nature07397 · Cited by 893
Targeted expression of MYCN causes neuroblastoma in transgenic mice
Weiss, W. A. (1997) · The EMBO Journal · doi:10.1093/emboj/16.11.2985 · Cited by 870
Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes
Molenaar, J. J., Koster, J., Zwijnenburg, D. A., van Sluis, P., Valentijn, L. J., van der Ploeg, I., Hamdi, M., van Nes, J., Westerman, B. A., van Arkel, J., et al. (2012) · Nature · doi:10.1038/nature10910 · Cited by 870
Matthay, K. K., Reynolds, C. P., Seeger, R. C., Shimada, H., Adkins, E. S., Haas-Kogan, D., Gerbing, R. B., London, W. B., & Villablanca, J. G. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.8925 · Cited by 858
Targeting natural killer cells and natural killer T cells in cancer
Vivier, E., Ugolini, S., Blaise, D., Chabannon, C., & Brossay, L. (2012) · Nature Reviews Immunology · doi:10.1038/nri3174 · Cited by 850
Iwahara, T., Fujimoto, J., Wen, D., Cupples, R., Bucay, N., Arakawa, T., Mori, S., Ratzkin, B., & Yamamoto, T. (1997) · Oncogene · doi:10.1038/sj.onc.1200849 · Cited by 726
Membrane-Bound IL-21 Promotes Sustained Ex Vivo Proliferation of Human Natural Killer Cells
Denman, C. J., Senyukov, V. V., Somanchi, S. S., Phatarpekar, P. V., Kopp, L. M., Johnson, J. L., Singh, H., Hurton, L., Maiti, S. N., Huls, M. H., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030264 · Cited by 683
Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition
Puissant, A., Frumm, S. M., Alexe, G., Bassil, C. F., Qi, J., Chanthery, Y. H., Nekritz, E. A., Zeid, R., Gustafson, W. C., Greninger, P., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0418 · Cited by 637
Correlating telomerase activity levels with human neuroblastoma outcomes
Hiyama, E., Hiyama, K., Yokoyama, T., Matsuura, Y., Piatyszek, M. A., & Shay, J. W. (1995) · Nature Medicine · doi:10.1038/nm0395-249 · Cited by 611
Park, J. R., DiGiusto, D. L., Slovak, M., Wright, C., Naranjo, A., Wagner, J., Meechoovet, H. B., Bautista, C., Chang, W.-C., Ostberg, J. R., et al. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300104 · Cited by 603
Chromosome 1p and 11q Deletions and Outcome in Neuroblastoma
Attiyeh, E. F., London, W. B., Mossé, Y. P., Wang, Q., Winter, C., Khazi, D., McGrady, P. W., Seeger, R. C., Look, A. T., Shimada, H., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052399 · Cited by 580
A novel retinoblastoma therapy from genomic and epigenetic analyses
Zhang, J., Benavente, C. A., McEvoy, J., Flores-Otero, J., Ding, L., Chen, X., Ulyanov, A., Wu, G., Wilson, M., Wang, J., et al. (2012) · Nature · doi:10.1038/nature10733 · Cited by 516
Self-citationCraddock, J. A., Lu, A., Bear, A., Pule, M., Brenner, M. K., Rooney, C. M., & Foster, A. E. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181ee6675 · Cited by 513
Diamond, M. S., & Springer, T. A. (1993) · The Journal of cell biology · doi:10.1083/jcb.120.2.545 · Cited by 505
Look, A. T., Hayes, F. A., Nitschke, R., McWilliams, N. B., & Green, A. A. (1984) · New England Journal of Medicine · doi:10.1056/nejm198407263110405 · Cited by 491
Association of Age at Diagnosis and Genetic Mutations in Patients With Neuroblastoma
Cheung, N.-K. V. (2012) · JAMA · doi:10.1001/jama.2012.228 · Cited by 468
Self-citationAllelic Loss of Chromosome 1p as a Predictor of Unfavorable Outcome in Patients with Neuroblastoma
Caron, H. N., Sluis, P. V., de Kraker, J., Bökkerink, J. P. M., Egeler, M., Laureys, G., Slater, R. M., Westerveld, A., Voûte, P. A., & Versteeg, R. (1996) · New England Journal of Medicine · doi:10.1056/nejm199601253340404 · Cited by 425
Cheung, N. K., Lazarus, H., Miraldi, F. D., Abramowsky, C. R., Kallick, S., Saarinen, U. M., Spitzer, T., Strandjord, S. E., Coccia, P. F., & Berger, N. A. (1987) · Journal of Clinical Oncology · doi:10.1200/jco.1987.5.9.1430 · Cited by 417
Self-citationEpitope Landscape in Breast and Colorectal Cancer
Segal, N. H., Parsons, D. W., Peggs, K. S., Velculescu, V., Kinzler, K. W., Vogelstein, B., & Allison, J. P. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-3095 · Cited by 416
Sausen, M., Leary, R. J., Jones, S., Wu, J., Reynolds, C. P., Liu, X., Blackford, A., Parmigiani, G., Diaz, L. A., Papadopoulos, N., et al. (2013) · Nature Genetics · doi:10.1038/ng.2493 · Cited by 414
Gm, B., Pritchard, J., Berthold, F., Nl, C., Castel, V., Castelberry, R. P., De Bernardi, B., Evans, A. E., Favrot, M., & Hedborg, F. (1994) · PubMed · Cited by 392
LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression
Molenaar, J. J., Domingo-Fernández, R., Ebus, M. E., Lindner, S., Koster, J., Drabek, K., Mestdagh, P., van Sluis, P., Valentijn, L. J., van Nes, J., et al. (2012) · Nature Genetics · doi:10.1038/ng.2436 · Cited by 383
(1982) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/68.4.589 · Cited by 376
Detection of ganglioside GD2 in tumor tissues and sera of neuroblastoma patients.
Schulz, G., Cheresh, D. A., Varki, N. M., Yu, A. L.-T., Staffileno, L. K., & Reisfeld, R. A. (1984) · PubMed · Cited by 368
Activated ALK Collaborates with MYCN in Neuroblastoma Pathogenesis
Zhu, S., Lee, J.-S., Guo, F., Shin, J., Perez-Atayde, A. R., Kutok, J. L., Rodig, S. J., Neuberg, D. S., Helman, D., Feng, H., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.010 · Cited by 365
Interleukin-15 biology and its therapeutic implications in cancer
Steel, J. C., Waldmann, T. A., & Morris, J. C. (2012) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2011.09.004 · Cited by 361
Germline Mutations of the Paired–Like Homeobox 2B (PHOX2B) Gene in Neuroblastoma
Trochet, D., Bourdeaut, F., Janoueix-Lerosey, I., Deville, A., de Pontual, L., Schleiermacher, G., Coze, C., Philip, N., Frébourg, T., Munnich, A., et al. (2004) · The American Journal of Human Genetics · doi:10.1086/383253 · Cited by 358
Vα24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages
Song, L., Asgharzadeh, S., Salo, J., Engell, K., Wu, H.-W., Sposto, R., Ara, T., Silverman, A. M., DeClerck, Y. A., Seeger, R. C., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37869 · Cited by 342
Mutation and cancer: neuroblastoma and pheochromocytoma.
Knudson, A. G., & Strong, L. C. (1972) · PubMed · Cited by 341
Anderson, D. J., & Axel, R. (1986) · Cell · doi:10.1016/0092-8674(86)90823-8 · Cited by 339
Phylogeny of multidrug transporters
Saier, Jr., & Paulsen, I. T. (2001) · Seminars in Cell & Developmental Biology · doi:10.1006/scdb.2000.0246 · Cited by 333
The ALKF1174L Mutation Potentiates the Oncogenic Activity of MYCN in Neuroblastoma
Berry, T., Luther, W., Bhatnagar, N., Jamin, Y., Poon, E., Sanda, T., Pei, D., Sharma, B., Vetharoy, W. R., Hallsworth, A., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.06.001 · Cited by 326
Self-citationVesicular neurotransmitter transporters: from bacteria to humans.
Schuldiner, S., Shirvan, A., & Linial, M. (1995) · Physiological Reviews · doi:10.1152/physrev.1995.75.2.369 · Cited by 326
Norris, M. D., Bordow, S. B., Marshall, G. M., Haber, P. S., Cohn, S. L., & Haber, M. (1996) · New England Journal of Medicine · doi:10.1056/nejm199601253340405 · Cited by 322
Chromosome 6p22 Locus Associated with Clinically Aggressive Neuroblastoma
Maris, J. M., Mosse, Y. P., Bradfield, J. P., Hou, C., Monni, S., Scott, R. H., Asgharzadeh, S., Attiyeh, E. F., Diskin, S. J., Laudenslager, M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708698 · Cited by 319
Integrative genomics identifies LMO1 as a neuroblastoma oncogene
Wang, K., Diskin, S. J., Zhang, H., Attiyeh, E. F., Winter, C., Hou, C., Schnepp, R. W., Diamond, M., Bosse, K., Mayes, P. A., et al. (2011) · Nature · doi:10.1038/nature09609 · Cited by 310
Trk Receptor Expression and Inhibition in Neuroblastomas
Brodeur, G. M., Minturn, J. E., Ho, R., Simpson, A. M., Iyer, R., Varela, C. R., Light, J. E., Kolla, V., & Evans, A. E. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1815 · Cited by 307
Common variations in BARD1 influence susceptibility to high-risk neuroblastoma
Capasso, M., Devoto, M., Hou, C., Asgharzadeh, S., Glessner, J. T., Attiyeh, E. F., Mosse, Y. P., Kim, C., Diskin, S. J., Cole, K. A., et al. (2009) · Nature Genetics · doi:10.1038/ng.374 · Cited by 305
Castriconi, R., Dondero, A., Augugliaro, R., Cantoni, C., Carnemolla, B., Sementa, A. R., Negri, F., Conte, R., Corrias, M. V., Moretta, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405025101 · Cited by 294
Clinical Significance of Tumor-Associated Inflammatory Cells in Metastatic Neuroblastoma
Asgharzadeh, S., Salo, J. A., Ji, L., Oberthuer, A., Fischer, M., Berthold, F., Hadjidaniel, M., Liu, C. W.-Y., Metelitsa, L. S., Pique-Regi, R., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.9169 · Cited by 285
Germline PHOX2B Mutation in Hereditary Neuroblastoma
Mosse, Y. P., Laudenslager, M., Khazi, D., Carlisle, A. J., Winter, C. L., Rappaport, E., & Maris, J. M. (2004) · The American Journal of Human Genetics · doi:10.1086/424530 · Cited by 284
Therapeutic intervention with complement and β-glucan in cancer
Ross, G. D., Větvička, V., Yan, J., Xia, Y., & Větvičková, J. (1999) · Immunopharmacology · doi:10.1016/s0162-3109(99)00013-2 · Cited by 283
Common variation at 6q16 within HACE1 and LIN28B influences susceptibility to neuroblastoma
Diskin, S. J., Capasso, M., Schnepp, R. W., Cole, K. A., Attiyeh, E. F., Hou, C., Diamond, M., Carpenter, E. L., Winter, C., Lee, H., et al. (2012) · Nature Genetics · doi:10.1038/ng.2387 · Cited by 266
Downregulation and/or Release of NKG2D Ligands as Immune Evasion Strategy of Human Neuroblastoma
Raffaghello, L., Prigione, I., Airoldi, I., Camoriano, M., Levreri, I., Gambini, C., Pende, D., Steinle, A., Ferrone, S., & Pistoia, V. (2004) · Neoplasia · doi:10.1593/neo.04316 · Cited by 264
Xu, H., Cheung, I. Y., Guo, H.-F., & Cheung, N.-K. V. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4517 · Cited by 264
Self-citationCheung, N.-K. V., Cheung, I. Y., Kushner, B. H., Ostrovnaya, I., Chamberlain, E., Kramer, K., & Modak, S. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.3807 · Cited by 263
Self-citationNatural Killer T Cells Infiltrate Neuroblastomas Expressing the Chemokine CCL2
Metelitsa, L. S., Wu, H.-W., Wang, H., Yang, Y., Warsi, Z., Asgharzadeh, S., Groshen, S., Wilson, S. B., & Seeger, R. C. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20031462 · Cited by 261
Neuroblastoma-derived gangliosides inhibit dendritic cell generation and function.
Shurin, G. V., Shurin, M. R., Быковская, С. Н., Shogan, J., Lotze, M. T., & Barksdale, E. M. (2001) · PubMed · Cited by 250
Shusterman, S., London, W. B., Gillies, S. D., Hank, J. A., Voss, S. D., Seeger, R. C., Reynolds, C. P., Kimball, J., Albertini, M. R., Wagner, B., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.8861 · Cited by 248
Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma
Kramer, K., Kushner, B. H., Modak, S., Pandit-Taskar, N., Smith-Jones, P., Zanzonico, P., Humm, J. L., Xu, H., Wolden, S. L., Souweidane, M. M., et al. (2010) · Journal of Neuro-Oncology · doi:10.1007/s11060-009-0038-7 · Cited by 247
Self-citationSafety and immunologic effects of IL-15 administration in nonhuman primates
Berger, C., Berger, M., Hackman, R. C., Gough, M., Elliott, C., Jensen, M. C., & Riddell, S. R. (2009) · Blood · doi:10.1182/blood-2008-12-189266 · Cited by 244
Asgharzadeh, S., Pique-Regi, R., Sposto, R., Wang, H., Yang, Y., Shimada, H., Matthay, K., Buckley, J., Ortega, A., & Seeger, R. C. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj330 · Cited by 237
Cytotoxicity of Activated Natural Killer Cells against Pediatric Solid Tumors
Cho, D., Shook, D. R., Shimasaki, N., Chang, Y.-H., Fujisaki, H., & Campana, D. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0735 · Cited by 234
Shukla, N., Ameur, N., Yilmaz, I., Nafa, K., Lau, C.-Y., Marchetti, A., Borsu, L., Barr, F. G., & Ladanyi, M. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2056 · Cited by 232
Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment
Tarek, N., Le Luduec, J.-B., Gallagher, M. M., Zheng, J., Venstrom, J. M., Chamberlain, E., Modak, S., Heller, G., Dupont, B., Cheung, N.-K. V., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci62749 · Cited by 229
Self-citationTelomeres and Telomerase: The Means to the End (Nobel Lecture)
Blackburn, E. H. (2010) · Angewandte Chemie International Edition · doi:10.1002/anie.201002387 · Cited by 226
Promising Therapeutic Targets in Neuroblastoma
Matthay, K. K., George, R. E., & Yu, A. L. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1939 · Cited by 187
Targeted Expression of Mutated ALK Induces Neuroblastoma in Transgenic Mice
Heukamp, L. C., Thor, T., Schramm, A., De Preter, K., Kumps, C., De Wilde, B., Odersky, A., Peifer, M., Lindner, S., Spruessel, A., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003967 · Cited by 181
Analysis of early human neural crest development
Betters, E., Liu, Y., Kjaeldgaard, A., Sundström, E., & García-Castro, M. I. (2010) · Developmental Biology · doi:10.1016/j.ydbio.2010.05.012 · Cited by 181
Kushner, B., & Cheung, N. (1989) · Blood · doi:10.1182/blood.v73.7.1936.1936 · Cited by 179
Self-citationDelgado, D. C., Hank, J. A., Kolesar, J., Lorentzen, D., Gan, J., Seo, S., Kim, K., Shusterman, S., Gillies, S. D., Reisfeld, R. A., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2211 · Cited by 179
Targeting ALK in neuroblastoma—preclinical and clinical advancements
Carpenter, E. L., & Mossé, Y. P. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.72 · Cited by 177
Yee, D., Favoni, R. E., Lebovic, G. S., Lombana, F., Powell, D. R., Reynolds, C. P., & Rosen, N. (1990) · Journal of Clinical Investigation · doi:10.1172/jci114910 · Cited by 175
Cyclin D1 and CDK4 Activity Contribute to the Undifferentiated Phenotype in Neuroblastoma
Molenaar, J. J., Ebus, M. E., Koster, J., Sluis, P. V., van Noesel, C. J. M., Versteeg, R., & Caron, H. N. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5032 · Cited by 171
Accumulation of Segmental Alterations Determines Progression in Neuroblastoma
Schleiermacher, G., Janoueix-Lerosey, I., Ribeiro, A., Klijanienko, J., Couturier, J., Pierron, G., Mosseri, V., Valent, A., Auger, N., Plantaz, D., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7955 · Cited by 168
ALK receptor tyrosine kinase promotes cell growth and neurite outgrowth
Motegi, A., Fujimoto, J., Kotani, M., Sakuraba, H., & Yamamoto, T. (2004) · Journal of Cell Science · doi:10.1242/jcs.01183 · Cited by 167
Nguyễn, L. B., Diskin, S. J., Capasso, M., Wang, K., Diamond, M. A., Glessner, J., Kim, C., Attiyeh, E. F., Mosse, Y. P., Cole, K., et al. (2011) · PLoS Genetics · doi:10.1371/journal.pgen.1002026 · Cited by 165
Modak, S. I., Kramer, K., Gultekin, S. H., Guo, H.-F., & Cheung, N. V. (2001) · PubMed · Cited by 164
Self-citationLiu, D., Song, L., Wei, J., Courtney, A. N., Gao, X., Marinova, E., Guo, L., Heczey, A., Asgharzadeh, S., Kim, E., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59535 · Cited by 164
Prevalence and functional consequence of PHOX2B mutations in neuroblastoma
Raabe, E. H., Laudenslager, M., Winter, C. L., Wasserman, N. F., Cole, K. A., LaQuaglia, M. P., Maris, D. J., Mossé, Y. P., & Maris, J. M. (2007) · Oncogene · doi:10.1038/sj.onc.1210659 · Cited by 162
Cheung, N. V., Guo, H.-F., Hu, J., Tassev, D. V., & Cheung, I. Y. (2012) · OncoImmunology · doi:10.4161/onci.19864 · Cited by 159
Self-citationSugiura, Y., Shimada, H., Seeger, R. C., Laug, W. E., & DeClerck, Y. A. (1998) · PubMed · Cited by 154
Coffey, D. C., Kutko, M. C., Glick, R. D., Butler, L. M., Heller, G., Rifkind, R. A., Marks, P. A., Richon, V. M., & LaQuaglia, M. P. (2001) · PubMed · Cited by 154
Trochet, D., Hong, S. J., Lim, J., Brunet, J., Münnich, A., Kim, K., Lyonnet, S., Goridis, C., & Amiel, J. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi401 · Cited by 149
Effect of Bortezomib on Human Neuroblastoma Cell Growth, Apoptosis, and Angiogenesis
Brignole, C., Marimpietri, D., Pastorino, F., Nico, B., Paolo, D. D., Cioni, M., Piccardi, F., Cilli, M., Pezzolo, A., Corrias, M. V., et al. (2006) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djj309 · Cited by 149
An integrative genomics screen uncovers ncRNA T-UCR functions in neuroblastoma tumours
Mestdagh, P., Fredlund, E., Pattyn, F., Rihani, A., Maerken, T. V., Vermeulen, J., Kumps, C., Menten, B., Preter, K. D., Schramm, A. R., et al. (2010) · Oncogene · doi:10.1038/onc.2010.106 · Cited by 148
Anderson, D. J., Carnahan, J., Michelsohn, A. M., & Patterson, P. (1991) · Journal of Neuroscience · doi:10.1523/jneurosci.11-11-03507.1991 · Cited by 140
Use of NK cell activity in cure by transplant
Leung, W. H. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2011.08823.x · Cited by 138
Anti-GD2 Antibody Therapy for GD2-Expressing Tumors
Navid, F., Santana, V. M., & Barfield, R. C. (2010) · Current Cancer Drug Targets · doi:10.2174/156800910791054167 · Cited by 135
Souttou, B., Carvalho, N. B.-D., Raulais, D., & Vigny, M. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m007333200 · Cited by 133
The Future Is Now: Chimeric Antigen Receptors as New Targeted Therapies for Childhood Cancer
Lee, D. W., Barrett, D. M., Mackall, C. L., Orentas, R. J., & Grupp, S. A. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1920 · Cited by 128
Henderson, M. J., Haber, M., Porro, A., Munoz, M. A., Iraci, N., Xue, C., Murray, J. E., Flemming, C. L., Smith, J. L., Fletcher, J. I., et al. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djr256 · Cited by 126
Dual IGF-I/II–Neutralizing Antibody MEDI-573 Potently Inhibits IGF Signaling and Tumor Growth
Gao, J., Chesebrough, J. W., Cartlidge, S. A., Ricketts, S., Incognito, L., Veldman-Jones, M. H., Blakey, D. C., Tabrizi, M. A., Jallal, B., Trail, P. A., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2274 · Cited by 124
Cheung, N. V., Sowers, R. S., Vickers, A. J., Cheung, I. Y., Kushner, B. H., & Gorlick, R. G. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.6011 · Cited by 122
Self-citationAn Integrated In Vitro and In Vivo High-Throughput Screen Identifies Treatment Leads for Ependymoma
Atkinson, J. M., Shelat, A. A., Carcaboso, A. M., Kranenburg, T. A., Arnold, L. A., Boulos, N., Wright, K. D., Johnson, R. A., Poppleton, H., Mohankumar, K. M., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.08.013 · Cited by 118
Autonomic neurocristopathy-associated mutations in PHOX2B dysregulate Sox10 expression
Nagashimada, M., Ohta, H., Li, C. V., Nakao, K., Uesaka, T., Brunet, J., Amiel, J., Trochet, D., Wakayama, T., & Enomoto, H. (2012) · Journal of Clinical Investigation · doi:10.1172/jci63401 · Cited by 118
Whiteford, C. C., Bilke, S., Greer, B. T., Chen, Q., Braunschweig, T. A., Cenacchi, N., Wei, J. S., Smith, M. A., Houghton, P. J., Morton, C. L., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-0610 · Cited by 108
Schulte, J. H., Bachmann, H. S., Brockmeyer, B., Preter, K. D., Oberthür, A., Ackermann, S., Kahlert, Y., Pajtler, K. W., Theißen, J., Westermann, F., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2809 · Cited by 107
Caruso, D. A., Orme, L. M., Amor, G. M., Neale, A. M., Radcliff, F. J., Downie, P., Tang, M. L. K., & Ashley, D. M. (2005) · Cancer · doi:10.1002/cncr.20911 · Cited by 106
Poremba, C., Scheel, C., Hero, B., Christiansen, H., Schaefer, K., Nakayama, J., Berthold, F., Juergens, H., Boecker, W., & Dockhorn‐Dworniczak, B. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.13.2582 · Cited by 104
Ragupathi, G., Livingston, P. O., Hood, C., Gathuru, J., Krown, S. E., Chapman, P. B., Wolchok, J. D., Williams, L. J., Oldfield, R. C., & Hwu, W. (2003) · PubMed · Cited by 103
Schulte, J. H., Lindner, S., Bohrer, A., et al. (2012) · Oncogene · doi:10.1038/onc.2012.106 · Cited by 103
Kushner, B. H., & Cheung, N. (1992) · Blood · doi:10.1182/blood.v79.6.1484.1484 · Cited by 101
Self-citationCarol, H., Boehm, I., Reynolds, C. P., Kang, M. H., Maris, J. M., Morton, C. L., Gorlick, R. G., Kolb, E. A., Keir, S. T., Wu, J., et al. (2011) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1618-8 · Cited by 99
Bosse, K. R., Diskin, S. J., Cole, K. A., Wood, A., Schnepp, R. W., Norris, G. T., Nguyễn, L. B., Jagannathan, J., LaQuaglia, M. P., Winter, C. L., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3703 · Cited by 97
Midkine and Alk signaling in sympathetic neuron proliferation and neuroblastoma predisposition
Reiff, T., Huber, L., Krämer, M., Delattre, O., Janoueix‐Lerosey, I., & Rohrer, H. (2011) · Development · doi:10.1242/dev.072157 · Cited by 96
Immunosurveillance and Survivin-Specific T-Cell Immunity in Children With High-Risk Neuroblastoma
Coughlin, C. M., Fleming, M. D., Carroll, R. G., Pawel, B., Hogarty, M. D., Shan, X., Vance, B. A., Cohen, J. N., Jairaj, S., Lord, E. M., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.3314 · Cited by 96
Neal, Z. C., Yang, J. C., Rakhmilevich, A. L., Buhtoiarov, I. N., Lum, H. E., Imboden, M., Hank, J. A., Lode, H. N., Reisfeld, R. A., Gillies, S. D., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0799 · Cited by 95
Ren, Y., Chan, H. M., Li, Z., Lin, C.-L. S., Nicholls, J. M., Chen, C. F., Lee, P. Y., Lui, V. C. H., Bacher, M., & Tam, P. K. H. (2004) · Oncogene · doi:10.1038/sj.onc.1207490 · Cited by 94
Faisal, A., Vaughan, L. S., Bavetsias, V., Sun, C., Atrash, B., Avery, S., Jamin, Y., Robinson, S. P., Workman, P., Blagg, J., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0333 · Cited by 94
Cheung, N. V., & Modak, S. I. (2002) · PubMed · Cited by 92
Self-citationBower, K., Napier, C. E., Cole, S. L., Dagg, R. A., Lau, L. M. S., Duncan, E. L., Moy, E. L., & Reddel, R. R. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050062 · Cited by 88
Single-agent interleukin-2 in the treatment of metastatic melanoma: A systematic review
Petrella, T. M., Quirt, I. C., Verma, S., Haynes, A. E., Charette, M. L., & Bak, K. (2007) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2007.04.003 · Cited by 87
Bao, L., DUNHAM, K. R., & Lucas, K. G. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1037-z · Cited by 86
Paracrine Signaling Through MYCN Enhances Tumor-Vascular Interactions in Neuroblastoma
Chanthery, Y. H., Gustafson, W. C., Itsara, M., Persson, A. I., Hackett, C. S., Grimmer, M., Charron, E., Yakovenko, S., Kim, G., Matthay, K. K., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3002977 · Cited by 84
Mitochondrial Bcl-2 Family Dynamics Define Therapy Response and Resistance in Neuroblastoma
Goldsmith, K. C., Gross, M., Peirce, S. K., Luyindula, D., Liu, X., Vu, A. T., Sliozberg, M., Guo, R. J., Zhao, H., Reynolds, C. P., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3603 · Cited by 81
Anti‐CD3 × anti‐GD2 bispecific antibody redirects T‐cell cytolytic activity to neuroblastoma targets
Yankelevich, M., Kondadasula, S. V., Thakur, A. B., Buck, S. A., Cheung, N. V., & Lum, L. G. (2012) · Pediatric Blood & Cancer · doi:10.1002/pbc.24237 · Cited by 80
Self-citationEvidence for a hereditary neuroblastoma predisposition locus at chromosome 16p12-13.
Maris, J. M., Weiss, M. J., Mossé, Y. P., Hii, G., Guo, C. H., White, P. S., Hogarty, M. D., Mirensky, T. L., Brodeur, G. M., Rebbeck, T. R., et al. (2002) · PubMed · Cited by 80
Neuroblastoma in adolescents: The Italian experience
Conte, M., Parodi, S., Bernardi, B. D., Milanaccio, C., Mazzocco, K., Angelini, P., Viscardi, E., Cataldo, A. D., Luksch, R., & Haupt, R. (2006) · Cancer · doi:10.1002/cncr.21751 · Cited by 79
Cheung, N. K., Guo, H.-F., Heller, G., & Cheung, I. Y. (2000) · PubMed · Cited by 79
Self-citationPhase II trial of hu14.18-IL2 for patients with metastatic melanoma
Albertini, M. R., Hank, J. A., Gadbaw, B., Kostlevy, J., Haldeman, J., Schalch, H., Gan, J., Kim, K., Eickhoff, J. C., Gillies, S. D., et al. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1286-5 · Cited by 77
Tanno, B., Mancini, C., Vitali, R., Mancuso, M., McDowell, H. P., Dominici, C., & Raschellà, G. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1479 · Cited by 75
Yang, R. K., Kalogriopoulos, N. A., Rakhmilevich, A. L., Ranheim, E. A., Seo, S., Kim, K., Alderson, K. L., Gan, J., Reisfeld, R. A., Gillies, S. D., et al. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1200934 · Cited by 73
Cheung, I. Y., Hsu, K. C., & Cheung, N. V. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.6236 · Cited by 72
Self-citationNormal human serum contains a natural IgM antibody cytotoxic for human neuroblastoma cells.
Ollert, M. W., David, K. A., Schmitt, C., Hauenschild, A., Bredehorst, R., Erttmann, R., & Vogel, C. W. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.9.4498 · Cited by 71
Long-lived and transferable tumor immunity in mice after targeted interleukin-2 therapy.
Becker, J. C., Varki, N. M., Gillies, S. D., Furukawa, K., & Reisfeld, R. (1996) · Journal of Clinical Investigation · doi:10.1172/jci119107 · Cited by 71
Antibody targeting of anaplastic lymphoma kinase induces cytotoxicity of human neuroblastoma
Carpenter, E. L., Haglund, E. A., Mace, E. M., Deng, D., Martínez, D., Wood, A., Chow, A. K., Weiser, D. A., Belcastro, L. T., Winter, C. L., et al. (2012) · Oncogene · doi:10.1038/onc.2011.647 · Cited by 70
T Cells Expressing Constitutively Active Akt Resist Multiple Tumor-associated Inhibitory Mechanisms
Sun, J., Dotti, G., Huye, L. E., Foster, A. E., Savoldo, B., Gramatges, M. M., Spencer, D. M., & Rooney, C. M. (2010) · Molecular Therapy · doi:10.1038/mt.2010.185 · Cited by 69
Pietras, A., Johnsson, A. S., & Påhlman, S. (2010) · Current topics in microbiology and immunology · doi:10.1007/82_2010_72 · Cited by 68
Bénard, J., Raguénez, G., Kauffmann, A., Valent, A., Ripoche, H., Joulin, V., Job, B., Danglot, G., Cantais, S., Robert, T., et al. (2008) · Molecular Oncology · doi:10.1016/j.molonc.2008.07.002 · Cited by 67
Bolesta, E., Kowalczyk, A., Wierzbicki, A. J., Rotkiewicz, P., Bambach, B. J., Tsao, C.-Y., Horwacik, I., Koliński, A., Rokita, H., Brecher, M. L., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2164 · Cited by 65
Chen, S., Caragine, T. A., Cheung, N. V., & Tomlinson, S. (2000) · PubMed · Cited by 65
Self-citationComparison of in vitro antibody-targeted cytotoxicity using mouse, rat and human effectors
Bergman, I., Basse, P. H., Barmada, M. A., Griffin, J. A., & Cheung, N. V. (2000) · Cancer Immunology Immunotherapy · doi:10.1007/s002620000120 · Cited by 65
Self-citationALK receptor activation, ligands and therapeutic targeting in glioblastoma and in other cancers
Wellstein, A. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00192 · Cited by 65
Survivin minigene DNA vaccination is effective against neuroblastoma
Fest, S., Huebener, N., Bleeke, M., Durmus, T., Stermann, A., Woehler, A., Baykan, B., Zenclussen, A. C., Michalsky, E., Jaeger, I. S., et al. (2009) · International Journal of Cancer · doi:10.1002/ijc.24291 · Cited by 65
Neuroblastoma epigenetics: From candidate gene approaches to genome-wide screenings
Decock, A., Ongenaert, M., Vandesompele, J., & Speleman, F. (2011) · Epigenetics · doi:10.4161/epi.6.8.16516 · Cited by 64
Ren, Y., Chan, H. M., Fan, J., Xie, Y., Chen, Y. X., Li, W. H., Jiang, G. P., Liu, Q., Meinhardt, A., & Tam, P. K. H. (2006) · Oncogene · doi:10.1038/sj.onc.1209395 · Cited by 64
Replication of Neuroblastoma SNP Association at the BARD1 Locus in African-Americans
Latorre, V., Diskin, S. J., Diamond, M. A., Zhang, H., Hakonarson, H. H., Maris, J. M., & Devoto, M. (2012) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-11-0830 · Cited by 61
Chesler, L., & Weiss, W. A. (2011) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2011.09.011 · Cited by 60
Coco, S., Theißen, J., Scaruffi, P., Stigliani, S., Moretti, S., Oberthuer, A., Valdora, F., Fischer, M., Gallo, F., Hero, B., et al. (2012) · International Journal of Cancer · doi:10.1002/ijc.27432 · Cited by 59
Degoutin, J. L., Carvalho, N. B.-D., Cifuentes-Díaz, C., & Vigny, M. (2009) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2008.06593.x · Cited by 57
Kushner, B. H., Kramer, K., Modak, S. I., & Cheung, N. V. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.3317 · Cited by 57
Self-citationBachetti, T., Paolo, D. D., Lascio, S. D., Mirisola, V., Brignole, C., Bellotti, M., Caffa, I., Ferraris, C., Fiore, M., Fornasari, D., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013108 · Cited by 56
Leaky Catecholamine Stores: Undue Waste or a Stress Response Coping Mechanism?
Eisenhofer, G., Kopin, I. J., & Goldstein, D. S. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1296.027 · Cited by 55
Crosswell, H. E., Dasgupta, A., Alvarado, C. S., Watt, T. C., Christensen, J. G., De, P. K. R., Durden, D. L., & Findley, H. W. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-411 · Cited by 53
Schönherr, C., Yang, H.-L., Vigny, M., Palmer, R. H., & Hallberg, B. (2010) · Oncogene · doi:10.1038/onc.2010.27 · Cited by 53
Morandi, F., Scaruffi, P., Gallo, F., Stigliani, S., Moretti, S., Bonassi, S., Gambini, C., Mazzocco, K., Fardin, P., Haupt, R., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0029922 · Cited by 49
Systems genetics analysis of cancer susceptibility: from mouse models to humans
Quigley, D. A., & Balmain, A. (2009) · Nature Reviews Genetics · doi:10.1038/nrg2617 · Cited by 48
Onitake, Y., Hiyama, E., Kamei, N., Yamaoka, H., Sueda, T., & Hiyama, K. (2009) · Journal of Pediatric Surgery · doi:10.1016/j.jpedsurg.2009.07.046 · Cited by 45
Ge, X., Wu, L., Hu, W., Fernandes, S. M., Wang, C., Li, X., Brown, J. R., & Qin, X. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0647 · Cited by 44
Jing, W., Yan, X., Hallett, W. H. D., Gershan, J. A., & Johnson, B. D. (2011) · Blood · doi:10.1182/blood-2010-12-326108 · Cited by 43
In silico Driven Redesign of a Clinically Relevant Antibody for the Treatment of GD2 Positive Tumors
Ahmed, M., Goldgur, Y., Hu, J., Guo, H.-F., & Cheung, N. V. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063359 · Cited by 42
Self-citationCharacterization and IL-15 dependence of NK cells in humanized mice
Pek, E. A., Chan, T., Reid, S., & Ashkar, A. A. (2010) · Immunobiology · doi:10.1016/j.imbio.2010.04.008 · Cited by 41
Levy, A. G., Zage, P. E., Akers, L. J., Ghisoli, M. L., Chen, Z., Fang, W., Kannan, S., Graham, T. C., Zeng, L., Franklin, A. R. K., et al. (2010) · Investigational New Drugs · doi:10.1007/s10637-010-9551-y · Cited by 40
Therapeutic targeting of miRNAs in neuroblastoma
Stallings, R. L., Foley, N. H., Bryan, K. R., Buckley, P. G., & Bray, I. M. (2010) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2010.510136 · Cited by 39
Theranostics: Evolution of the Radiopharmaceutical Meta-Iodobenzylguanidine in Endocrine Tumors
Sisson, J. C., & Yanik, G. A. (2012) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2011.11.004 · Cited by 37
Zhao, Q., Feng, Y., Zhu, Z., & Dimitrov, D. S. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0281 · Cited by 36
Huber, K., Franke, A., Brühl, B., Krispin, S., Ernsberger, U., Schober, A., Halbach, O. V. B. U., Rohrer, H., Kalcheim, C., & Unsicker, K. (2008) · Neural Development · doi:10.1186/1749-8104-3-28 · Cited by 33
Quiescence and γH2AX in neuroblastoma are regulated by ouabain/Na,K-ATPase
Hiyoshi, H., Abdelhady, S., Segerström, L., Sveinbjørnsson, B., Nuriya, M., Lundgren, K. C., Desfrere, L., Miyakawa, A., Yasui, M., Kogner, P., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.159 · Cited by 32
Ladenstein, R. L., Pötschger, U., Siabalis, D., Garaventa, A., Bergeron, C., Lewis, I. J., Stein, J., Kohler, J., Shaw, P. J., Holter, W., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.5465 · Cited by 32
Neuroblastoma genetics and phenotype: A tale of heterogeneity
Speleman, F., Preter, K. D., & Vandesompele, J. (2011) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2011.07.003 · Cited by 27
VCN-Releasable sialic acid and gangliosides in human neuroblastomas
Shochat, S. J., Abt, A. B., & Schengrund, C. (1977) · Journal of Pediatric Surgery · doi:10.1016/0022-3468(77)90019-7 · Cited by 26
Petroni, M., Veschi, V., Gulino, A., & Giannini, G. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00141 · Cited by 25
Huebener, N., Fest, S., Hilt, K., Schramm, A. R., Eggert, A., Durmus, T., Woehler, A., Stermann, A., Bleeke, M., Baykan, B., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0107 · Cited by 25
Abel, A. (2009) · International Journal of Oncology · doi:10.3892/ijo_00000196 · Cited by 25
Can the exome and the immunome converge on the design of efficient cancer vaccines?
Kroemer, G., & Zitvogel, L. (2012) · OncoImmunology · doi:10.4161/onci.20730 · Cited by 24
Neuroblastoma: Issues in Transplantation
Grupp, S. A., Asgharzadeh, S., & Yanik, G. A. (2012) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2011.10.020 · Cited by 18
Louis, C. U., & Brenner, M. K. (2009) · Current Pharmaceutical Design · doi:10.2174/138161209787315765 · Cited by 13
Cited by
Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours
Ma, X., Liu, Y., Liu, Y., Alexandrov, L. B., Edmonson, M. N., Gawad, C., Zhou, X., Li, Y., Rusch, M. C., Easton, J., et al. (2018) · Nature · doi:10.1038/nature25795 · Cited by 901
Nano-targeted induction of dual ferroptotic mechanisms eradicates high-risk neuroblastoma
Hassannia, B., Wiernicki, B., Ingold, I., Qu, F., Van Herck, S., Tyurina, Y. Y., Bayır, H., Abhari, B. A., Angeli, J. P. F., Choi, S. M., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci99032 · Cited by 627
Ladenstein, R., Pötschger, U., Valteau-Couanet, D., Luksch, R., Castel, V., Yaniv, I., Laureys, G., Brock, P., Michon, J. M., Owens, C., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30578-3 · Cited by 418
Irwin, M. S., & Park, J. R. (2015) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2014.09.015 · Cited by 392
Bresler, S. C., Weiser, D. A., Huwe, P. J., Park, J. H., Krytska, K., Ryles, H., Laudenslager, M., Rappaport, E. F., Wood, A. C., McGrady, P. W., et al. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.09.019 · Cited by 388
Metadata
- Authors
- Cheung, N.-K. V., & Dyer, M. A.
- Venue
- Nature Reviews Cancer
- Published
- 2013-05-24
- Volume
- 13
- Issue
- 6
- Pages
- 397-411
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2095296988
- Cited by
- 801
- References
- 182
- FWCI
- 8.46
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.